News

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...
Laconia Daily Sun5d
Weight-loss injections are dominating the market: Where will GLP-1 pills fit in?
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...
Scientific American1d
Could China’s New GLP-1 Drugs Beat Out Ozempic?
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years
Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes ...
Network-1 Commences Patent Litigation Against Samsung Entities
NEW CANAAN, CT / ACCESS Newswire / June 30, 2025 / Network-1 T, Inc. (NYSE:NTIP) announced today that it has initiated patent ...
TCTMD5d
Amylin Analogue Boosts Weight Loss When Added to GLP-1
Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...
European Medical Journal6d
Study Flags Autoimmune Concerns with GLP-1 Use
GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...
Mirage News6d
GLP-1 Users With Pancreatitis Sought by Biobank
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro ...
Pharmabiz2d
China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management
China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...
HealthDay on MSN1d
Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...
Pharmabiz6d
Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735
Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...